Abstract 494P
Background
The study aimed to assess the effects of a modified electric field patch operation method on scalp adverse reactions in glioblastoma patients undergoing tumor treating fields (TTFields).
Methods
A total of 73 glioblastoma patients who received TTFields between May 2019 and July 2022 were included in the study. The control group consisted of 36 patients treated with the conventional electric field patch operation method before April 2021, while the modified group included 37 patients treated after May 2021 using an improved technique for adhesion and removal of the electric field patch. The study conducted a comparison between two groups regarding the incidence of adverse scalp reactions and compliance with TTFields.
Results
The modified group exhibited significantly lower rates of scalp pruritus (P=0.0246), contact dermatitis (P=0.0253), and skin ulceration (P=0.0299) compared to the control group. Additionally, compliance with TTFields was notably higher in the modified group (81.1%) than in the control group (52.8%) with a statistically significant difference (P=0.0101). Furthermore, the incidence of adverse scalp reactions displayed seasonal variability, with the highest rates observed in summer (56.16%) and the lowest in winter (8.22%). Following the implementation of the adjusted electric field patch operation technique, a notable decrease in the incidence of adverse scalp reactions during the summer (P=0.0002), autumn (P=0.0411), and spring (P=0.0342) seasons was observed.
Conclusions
The utilization of this modified method has demonstrated efficacy in mitigating scalp adverse reactions, minimizing treatment disruptions, and enhancing adherence to TTFields therapy among patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16